Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation

J Allergy Clin Immunol. 2015 Feb;135(2):551-3. doi: 10.1016/j.jaci.2014.12.1867.
No abstract available

Publication types

  • Letter

MeSH terms

  • Candidiasis, Chronic Mucocutaneous / drug therapy*
  • Candidiasis, Chronic Mucocutaneous / genetics*
  • Heterozygote
  • Humans
  • Mutation*
  • Nitriles
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrazoles / therapeutic use*
  • Pyrimidines
  • STAT1 Transcription Factor / genetics*
  • Treatment Outcome

Substances

  • Nitriles
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyrimidines
  • STAT1 Transcription Factor
  • ruxolitinib